ERBB3 and neoplasm: He described how human epidermal growth factor receptor (HER) 2 and HER3 networks become upregulated when epidermal growth factor receptor (EGFR) alone is targeted, resulting in a tumour developing resistance to monotherapy, whereas a triplet therapy regimen to hit all the three surpassed any doublet in limiting tumour growth in mouse models.